Hikma Pharmaceuticals
Company Details
Linkedin ID:
hikma-pharmaceuticals
Website:
Employees number:
10,222
Number of followers:
627,035
NAICS:
3254
Industry Type:
Homepage:
hikma.com
IP Addresses:
31
Company ID:
HIK_2329616
Scan Status:
Completed
Hikma Pharmaceuticals Company CyberSecurity Posture
hikma.com
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Hikma Pharmaceuticals A.I CyberSecurity Scoring
Hikma Pharmaceuticals Risk Score (AI oriented)Between 750 and 799
Hikma Pharmaceuticals
Updated:
- Powered by our proprietary A.I cyber incident model
- Insurance preferes TPRM score to calculate premium
Hikma Pharmaceuticals Global Score (TPRM)XXXX
Hikma Pharmaceuticals
- Instant access to detailed risk factors
- Benchmark vs. industry & size peers
- Vulnerabilities
- Findings
Hikma Pharmaceuticals Company CyberSecurity News & History
Past Incidents
0
Attack Types
0
No data available
Hikma Pharmaceuticals Company Scoring based on AI Models
Cyber Incidents Likelihood 3 - 6 - 9 months
A.I Risk Score Likelihood 3 - 6 - 9 months
Underwriter Stats for Hikma Pharmaceuticals
Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2025.
Incidents vs All-Companies Average (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2025.
Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2025.
Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)
Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries
Hikma Pharmaceuticals Company Subsidiaries
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Loading...
Hikma Pharmaceuticals Similar Companies
MACLEODS PHARMACEUTICALS LTD.
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment.
Astellas Pharma
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneer
The Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving ac
Sandoz
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health c
Takeda
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by list
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the pa
Servier
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its
MENARINI Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic
At Teva, we're proud to be a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, our commitment to bettering health has never wavered. Every day, we challenge ourselves to p
.png)
Hikma Pharmaceuticals CyberSecurity News
November 14, 2025 08:00 AM
Directors’ Deals: Hikma Pharma director eyes recovery
A downbeat trading statement on November 6 proved a bitter pill to swallow for shareholders in Hikma Pharmaceuticals.
November 06, 2025 08:00 AM
Hikma Pharmaceuticals shares slump as lowers mid-term outlook
Hikma Pharmaceuticals PLC on Thursday reduced medium term guidance and cut the top-end of its 2025 core operating profit view amid a delayed...
September 19, 2025 07:00 AM
Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company
Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...
August 10, 2025 07:00 AM
One Hikma Pharmaceuticals Insider Raised Stake By 14% In Previous Year
LSE:HIK 1 Year Share Price vs Fair Value Explore Hikma Pharmaceuticals's Fair Values from the Community and select...
July 21, 2025 07:00 AM
Hikma Pharmaceuticals (LON:HIK) shareholders have earned a 8.3% CAGR over the last three years
By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...
May 29, 2025 07:00 AM
Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’
Amman, Jordan – Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default...
May 26, 2025 07:00 AM
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
The US Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection.
May 08, 2025 07:00 AM
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case
Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version...
March 08, 2025 08:00 AM
Hikma races to launch generic versions of blockbuster obesity drugs
Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year.
Frequently Asked Questions
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
Hikma Pharmaceuticals CyberSecurity History Information
Official Website of Hikma Pharmaceuticals
The official website of Hikma Pharmaceuticals is http://www.hikma.com.
Hikma Pharmaceuticals’s AI-Generated Cybersecurity Score
According to Rankiteo, Hikma Pharmaceuticals’s AI-generated cybersecurity score is 769, reflecting their Fair security posture.
How many security badges does Hikma Pharmaceuticals’ have ?
According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?
According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.
Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?
According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.
Does Hikma Pharmaceuticals comply with GDPR ?
According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.
Does Hikma Pharmaceuticals have PCI DSS certification ?
According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.
Does Hikma Pharmaceuticals comply with HIPAA ?
According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.
Does Hikma Pharmaceuticals have ISO 27001 certification ?
According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Industry Classification of Hikma Pharmaceuticals
Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.
Number of Employees at Hikma Pharmaceuticals
Hikma Pharmaceuticals employs approximately 10,222 people worldwide.
Subsidiaries Owned by Hikma Pharmaceuticals
Hikma Pharmaceuticals presently has no subsidiaries across any sectors.
Hikma Pharmaceuticals’s LinkedIn Followers
Hikma Pharmaceuticals’s official LinkedIn profile has approximately 627,035 followers.
NAICS Classification of Hikma Pharmaceuticals
Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
Hikma Pharmaceuticals’s Presence on Crunchbase
Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.
Hikma Pharmaceuticals’s Presence on LinkedIn
Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.
Cybersecurity Incidents Involving Hikma Pharmaceuticals
As of December 14, 2025, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.
Number of Peer and Competitor Companies
Hikma Pharmaceuticals has an estimated 5,432 peer or competitor companies worldwide.
Hikma Pharmaceuticals CyberSecurity History Information
How many cyber incidents has Hikma Pharmaceuticals faced ?
Total Incidents: According to Rankiteo, Hikma Pharmaceuticals has faced 0 incidents in the past.
What types of cybersecurity incidents have occurred at Hikma Pharmaceuticals ?
Incident Types: The types of cybersecurity incidents that have occurred include .
Incident Details
What are the most common types of attacks the company has faced ?
Additional Questions
.png)
Latest Global CVEs (Not Company-Specific)
Description
A weakness has been identified in itsourcecode Online Pet Shop Management System 1.0. This vulnerability affects unknown code of the file /pet1/addcnp.php. This manipulation of the argument cnpname causes sql injection. The attack can be initiated remotely. The exploit has been made available to the public and could be exploited.
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
A security flaw has been discovered in Tenda AX9 22.03.01.46. This affects the function image_check of the component httpd. The manipulation results in use of weak hash. It is possible to launch the attack remotely. A high complexity level is associated with this attack. It is indicated that the exploitability is difficult. The exploit has been released to the public and may be exploited.
Risk Information
cvss2
Base: 2.6
Severity: HIGH
AV:N/AC:H/Au:N/C:N/I:P/A:N
cvss3
Base: 3.7
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
A weakness has been identified in code-projects Student File Management System 1.0. This issue affects some unknown processing of the file /admin/update_student.php. This manipulation of the argument stud_id causes sql injection. The attack is possible to be carried out remotely. The exploit has been made available to the public and could be exploited.
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
A security flaw has been discovered in code-projects Student File Management System 1.0. This vulnerability affects unknown code of the file /admin/save_user.php. The manipulation of the argument firstname results in sql injection. The attack can be executed remotely. The exploit has been released to the public and may be exploited.
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
A vulnerability was identified in code-projects Student File Management System 1.0. This affects an unknown part of the file /admin/update_user.php. The manipulation of the argument user_id leads to sql injection. Remote exploitation of the attack is possible. The exploit is publicly available and might be used.
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Access Data Using Our API
Get company history
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?linkedin_id=hikma-pharmaceuticals' -H 'apikey: YOUR_API_KEY_HERE'
RapidWhat Do We Measure ?
Incident
Finding
Grade
Digital Assets
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
These are some of the factors we use to calculate the overall score:
Network Security
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
SBOM (Software Bill of Materials)
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
CMDB (Configuration Management Database)
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Threat Intelligence
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.
